Exelixis reported mixed results from its Phase 3 STELLAR-303 trial for the cancer drug zanzalintinib. The trial evaluated the drug in combination with atezolizumab. Final analysis for overall survival in metastatic colorectal cancer patients without active liver metastases showed a positive trend. However, this primary endpoint failed to achieve statistical significance.
Exelixis shares declined following the trial update.
The trial's other primary endpoint for overall survival in the entire patient population previously met its goal. Those results achieved statistical significance. The U.S. Food and Drug Administration accepted the company's new drug application based on the successful outcome. The agency expects to make a decision by December 3, 2026.